-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

Benzinga·08/14/2026 18:23:48
Listen to the news
B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.